Shukra Pharmaceuticals Limited announced the approval for listing and commencement of regular trading of its equity shares on the Main Board of the National Stock Exchange of India Limited (NSE). This represents a direct listing from the Bombay Stock Exchange (BSE), where the company's shares will continue to trade, implementing a dual-listing strategy.
The trading on NSE is scheduled to commence on Friday, 14 August 2026. The company marked this milestone with a ceremonial opening bell ringing at the NSE Exchange Plaza in Mumbai on that date.
Trading Identifiers and Details
- NSE Trading Symbol: SHUKRAPHAR
- International Securities Identification Number (ISIN): INE551C01044
- Market Segment: Main Board Equity (Normal Rolling Market)
- Base Reference Price: Derived from the closing price of the equity shares on the BSE on August 13, 2026.
Management Commentary
Mr. Dakshesh Shah, Managing Director of Shukra Pharmaceuticals Limited, stated that the NSE listing marks a major milestone in the company's corporate journey, reflecting its strong financial health and operational scaling. The stated purposes for the dual listing are:
- Expanding reach to institutional investors
- Increasing market liquidity
- Moving closer to the goal of becoming a premier name in global pharmaceutical manufacturing
- Offering a more accessible platform for new investors
- Demonstrating transparent corporate governance and shareholder trust
Company Background
Shukra Pharmaceuticals Limited is an India-based pharmaceutical company engaged in the manufacturing and marketing of a wide range of generic pharmaceutical formulations. The company operates with state-of-the-art facilities compliant with current good manufacturing practices (cGMP), manufacturing tablets, capsules, and liquid injections for both domestic public healthcare demands and international distribution networks.
Forward-Looking Statements
The release contains a standard disclaimer that statements not historical facts may constitute forward-looking statements involving risks, macroeconomic uncertainties, and regulatory variables that could cause actual operational outcomes to differ materially from those projected.